Kenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $18.19, for a total value of $272,850.00. Following the sale, the chief executive officer now owns 408,035 shares of the company’s stock, valued at $7,422,156.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

REGENXBIO Stock Down 5.4 %

Shares of REGENXBIO stock opened at $16.11 on Friday. The stock’s fifty day moving average is $20.03 and its two-hundred day moving average is $17.84. The company has a market capitalization of $790.03 million, a PE ratio of -2.67 and a beta of 1.29. REGENXBIO Inc. has a 52 week low of $11.83 and a 52 week high of $28.80.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.16). The business had revenue of $22.30 million during the quarter, compared to the consensus estimate of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. The business’s revenue was down 28.8% compared to the same quarter last year. During the same period last year, the company earned ($1.38) EPS. As a group, research analysts anticipate that REGENXBIO Inc. will post -3.98 earnings per share for the current year.

Hedge Funds Weigh In On REGENXBIO

Hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its holdings in shares of REGENXBIO by 73.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after buying an additional 746 shares during the period. Captrust Financial Advisors lifted its holdings in shares of REGENXBIO by 742.1% in the 1st quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company’s stock worth $32,000 after buying an additional 846 shares during the period. Royal Bank of Canada lifted its holdings in shares of REGENXBIO by 189.8% in the 3rd quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company’s stock worth $37,000 after buying an additional 915 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of REGENXBIO in the 4th quarter worth $38,000. Finally, Point72 Middle East FZE purchased a new stake in shares of REGENXBIO in the 4th quarter worth $52,000. Institutional investors own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on RGNX. Wedbush restated a “neutral” rating and set a $21.00 price target on shares of REGENXBIO in a research note on Wednesday, February 28th. Raymond James reaffirmed an “outperform” rating and set a $45.00 price objective on shares of REGENXBIO in a research report on Wednesday, February 21st. Royal Bank of Canada raised REGENXBIO from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $20.00 to $35.00 in a research report on Friday, March 8th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Thursday, April 11th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $40.00 price objective on shares of REGENXBIO in a research report on Friday, April 12th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.45.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.